Mission Statement, Vision, & Core Values of Statera Biopharma, Inc. (STAB)

When you look at Statera Biopharma, Inc. (STAB), the financials tell a story of extreme risk-a TTM (trailing twelve months) net loss of nearly -$95.43 million against a minuscule market capitalization of roughly $7.14 thousand as of late 2025. But what does the company's core purpose say about the long-term bet they are placing, especially when their mission is to 'rebalance the body's immune system and restore homeostasis' in the face of autoimmune diseases and cancer? Honestly, how can a company with a market cap this small pursue such a massive, life-changing vision?

That enormous gap between their financial reality and their scientific ambition is exactly why we need to dissect their Mission Statement, Vision, and Core Values. Are they just aspirational filler, or do they outline a precise, actionable strategy that could justify the massive volatility and the 'bearish' sentiment the stock has seen this year? Let's look past the penny-stock price of $0.0001 and see what guiding principles are actually driving the pipeline.

Statera Biopharma, Inc. (STAB) Overview

You're looking at Statera Biopharma, Inc. (STAB) and trying to figure out if the underlying science justifies the current valuation, and honestly, that's the right question to ask for a clinical-stage company. The direct takeaway is that while the stock trades at a nominal price, the company's core value lies entirely in its proprietary drug pipeline, which is now being monetized through strategic licensing deals.

Statera Biopharma, Inc. was founded in 2003 and then significantly restructured in 2021 through a merger with Cytocom, Inc., pivoting to a focus on novel immunotherapies. Its mission centers on restoring immune health by leveraging complex pleiotropic beneficial effects-meaning one drug can have multiple positive effects on the body's immune system (homeostasis). The company's core intellectual property is its extensive platform of Toll-like Receptor (TLR) agonists and antagonists, which are key proteins in the innate immune system.

As a clinical-stage firm, Statera Biopharma, Inc.'s primary business is drug development, not commercial sales. Current sales, as measured by the latest trailing twelve months (TTM) revenue, stand at approximately $3.69 million, a figure that largely reflects grants and licensing revenue rather than product sales. The company's pipeline includes candidates like STAT-201 for pediatric Crohn's disease and STAT-401 for pancreatic cancer. The most advanced compound, Entolimod (a TLR5 agonist), is the one driving recent financial activity.

Monetizing the Pipeline: 2025 Financial Performance

When you look at the financials, you need to swap the typical metric of 'record-breaking revenue' for 'record-breaking intellectual property (IP) monetization.' Here's the quick math: the company's TTM net loss remains substantial at about -$91.83 million, and the stock price is just $0.0001 as of November 20, 2025. Still, the underlying IP is valuable.

The most important financial event of the 2025 fiscal year was the deal with Tivic Health Systems, Inc. In March 2025, Tivic Health exercised an exclusive option for the Neutropenia indication of Entolimod, accelerating a milestone payment of $500,000 to Statera Biopharma, Inc. This payment, plus the issuance of shares to Statera Biopharma, Inc., is the clearest 2025 cash inflow from a main product. This is a crucial signal.

This licensing deal is the company's near-term lifeline, but the balance sheet shows the risks. The current ratio, a measure of short-term liquidity, is extremely low at just 0.05, which defintely flags significant capital constraints. You should view this as a high-risk, high-reward play where the value is in the pipeline, not the current cash flow.

• TTM Revenue: $3.69 million (primarily non-product).
• 2025 Milestone Payment: $500,000 (from Entolimod license).
• TTM Net Loss: -$91.83 million.
• Current Ratio: 0.05 (signals liquidity pressure).

The Pan-TLR Platform as an Industry Leader

You can't call Statera Biopharma, Inc. a market cap leader in the traditional sense; its market capitalization is only around $7.14K. However, its true leadership position is in its proprietary Pan-TLR Platform, a comprehensive suite of Toll-like Receptor agonists and antagonists designed to rebalance the body's immune system. This focus on immune restoration is a cutting-edge area of biopharma.

The fact that Tivic Health Systems, Inc. acquired the rights to Entolimod, a Phase III-ready asset for Acute Radiation Syndrome (ARS) with Fast Track Designation, demonstrates that Statera Biopharma, Inc.'s IP is highly valued by other players in the industry. The platform is designed to elicit a robust, durable response of antigen-specific killer T-cells, which is the holy grail for treating complex conditions like cancer and autoimmune diseases.

The company's success, therefore, isn't measured in quarterly sales today but in the validation of its science through these licensing deals. The next step is to understand the players betting on this science. You can find out more about the stakeholders in this complex story by Exploring Statera Biopharma, Inc. (STAB) Investor Profile: Who's Buying and Why?

Statera Biopharma, Inc. (STAB) Mission Statement

You're looking for the bedrock of Statera Biopharma, Inc.'s (STAB) strategy, and it's right there in their core focus: creating next-generation immune therapies that drive immune restoration and homeostasis. This isn't just corporate fluff; it's the guiding principle for a clinical-stage biopharmaceutical company operating in a high-risk, high-reward space.

This mission is the lens through which you must view their financials. As of November 2025, Statera Biopharma's market capitalization sits at a tiny $7.14K, which tells you this is a micro-cap play with significant volatility. For the last 12 months, the company reported revenue of approximately $3.69 million against substantial losses of around -$91.83 million. That massive loss shows the cost of their commitment to long-term, complex drug development over immediate profitability. It's a classic biopharma trade-off.

For more on the company's trajectory, you can read Statera Biopharma, Inc. (STAB): History, Ownership, Mission, How It Works & Makes Money.

Core Component 1: Immune Restoration and Homeostasis

The first pillar of the mission is the commitment to restoring balance (homeostasis) in the body's immune system. Most traditional immunotherapies work by either blunting or exaggerating a single factor; Statera Biopharma's approach is fundamentally different. They aim to harmonize the entire immune orchestra.

This is executed through their proprietary platform, the Advanced Immunomodulating Multi-Component System (AIMS). AIMS is designed to target complex pathways and engage multiple toll-like receptors (TLRs), rather than a one-dimensional approach. This focus on a multi-component system is their bet against the high failure rate of single-target drugs. Honestly, it's a smart way to de-risk the R&D process, but it is defintely a long-game strategy.

• Harmonize the immune orchestra.
• Target complex pathways, not single factors.
• Restore balance for protective immunity.

Core Component 2: Next-Generation Immune Therapies (Innovation)

The second component centers on innovation: developing 'next-generation' therapies. This means moving beyond existing treatment paradigms, specifically by leveraging pleiotropic drug effects (a single drug acting on multiple targets). They are looking for greater accuracy and therapeutic benefit that other published immunotherapies haven't achieved.

A concrete example of this is their late-stage TLR5 agonist, Entolimod. In February 2025, the company announced it had acquired worldwide exclusive license rights to Entolimod from Tivic Health Systems. This deal transformed Tivic Health Systems from a single-product company, which shows the market value of Statera Biopharma's innovative pipeline assets, even as the company itself navigates financial headwinds. This is a clear signal that their innovation is attracting external capital and validation.

Core Component 3: Addressing Unmet Medical Needs

The final, and most empathetic, component is the focus on addressing unmet medical needs in areas of significant patient suffering. This is the 'why' behind the R&D spend. Their pipeline is explicitly targeting a diverse range of challenging conditions:

• Autoimmune diseases (like Crohn's disease, STAT-201 program).
• Cancers (like pancreatic cancer, STAT-401 program).
• Emerging viruses.
• Neutropenia/anemia.

The commitment here is real, but you must acknowledge the financial reality: the high burn rate for R&D is why the company's Return on Equity (ROE) is deeply negative, sitting at about -286.94%. This metric is a stark reminder that in biopharma, the commitment to high-quality, life-changing products often comes with years of massive losses before a potential breakthrough. They are investing heavily in the future of patient care, but it's a volatile investment today.

Statera Biopharma, Inc. (STAB) Vision Statement

You need a clear map of what Statera Biopharma, Inc. is actually trying to build, especially given the stock's trading reality at $0.0001 per share as of November 20, 2025, on the OTC Pink Open Market. The company's vision, though not a single corporate slogan, is a clear mandate: Restoring Immune Health through next-generation immune therapies that focus on immune restoration and homeostasis. This vision is a high-stakes bet, as the company is operating with a trailing 12-month net loss of -$91.83 million against a modest revenue of $3.69 million in the same period, according to 2025 fiscal year data.

The core of the strategy is not just to treat symptoms but to re-balance the body's immune system. This is a crucial distinction in the biopharma space, but it requires substantial, defintely consistent capital, which is a major risk given the current market capitalization is only about $7.14K.

Restoring Immune Health: The Core Vision

The primary vision for Statera Biopharma, Inc. is centered on achieving immune restoration and homeostasis (a state of stable equilibrium). This is a complex, multi-target approach, moving beyond the industry's traditional one-drug, one-target model. Honestly, this is the company's single biggest differentiator, but it requires them to prove efficacy across multiple disease states simultaneously.

The goal is to develop therapies that elicit a robust and durable response of antigen-specific killer T-cells and antibodies to fight autoimmune, inflammatory, and infectious diseases, plus certain cancers. This is a massive undertaking for a company with only 72.58 million shares outstanding and a challenging financial profile.

• Develop next-generation immune therapies.
• Target complex immune pathways, not single factors.
• Restore immune balance, not just suppress inflammation.

The AIMS Platform: A Multi-Component Strategy

The company's core value proposition is built on its proprietary Advanced Immunomodulating Multi-component System (AIMS) platform. This platform is the engine for the vision, allowing the team to rapidly assess how novel compositions impact multiple pharmacokinetic-pharmacodynamic relationships-the study of how a drug affects the body and how the body affects the drug.

The AIMS platform is supposed to harmonize the immune orchestra, which means targeting multiple complex pathways to restore balance, rather than just blunting a single factor. Here's the quick math on the need for efficiency: with a trailing 12-month operating cash flow of -$12.86 million, the R&D process must be highly capital-efficient to sustain the pipeline. The AIMS platform is designed to discover targets with improved activity not achieved by single-target immunotherapies.

Pipeline Advancement and Strategic Realignment

The company's near-term opportunities and risks are mapped directly to its clinical pipeline, which is the action component of the vision. The pipeline includes several key candidates, but strategic realignment has already occurred to manage capital.

A major action was the February 2025 licensing deal where Tivic Health Systems, Inc. acquired exclusive worldwide rights to the late-stage TLR5 agonist, Entolimod, for acute radiation syndrome (ARS). This move provided an immediate cash infusion and offloaded the development cost for a Phase III asset.

Still, the core development focus remains on:

• STAT-201: Phase 3 clinical development plan for pediatric Crohn's patients.
• STAT-205: Clinical trial initiated for acute and post-acute COVID infections (Long-Haulers).

The ability to execute on these trials, especially STAT-201 with its Orphan Drug Designation, will be the true test of the company's commitment to its vision. What this estimate hides is the extreme pressure from the negative return on equity (ROE) of -286.94%, making every dollar spent on the pipeline a high-risk, high-reward proposition. You can get a deeper dive into the numbers Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors.

Statera Biopharma, Inc. (STAB) Core Values

You're looking past the noise of a micro-cap stock and trying to understand the fundamental drive behind Statera Biopharma, Inc. (STAB). That's smart. The mission and values of a clinical-stage biopharma company, especially one with a market capitalization around $7.14K as of November 20, 2025, are the true indicators of its long-term potential, not the current $0.0001 stock price. Their core is built on three guiding principles, all centered on immune restoration.

The company's foundation is explicitly about 'Restoring Immune Health,' a complex goal that requires an authoritative, multi-faceted approach. This isn't just about single-target drug development; it's a systems-level philosophy. Here's how their actions map to their core, unstated values.

Scientific Innovation & Systems Thinking

This value is the engine of Statera Biopharma, Inc., manifesting in their Advanced Immunomodulating Multi-component System (AIMS) platform. They reject the one-dimensional approach of blunting or exaggerating a single factor. Instead, the AIMS platform is designed to comprehensively engage the immune system, much like an orchestra, to restore balance (homeostasis). This is a critical distinction in the biotech space.

• Screening compositions that hit multiple pathways in multiple cell types.
• Using computational methods and Artificial Intelligence (AI) to integrate data and evolve composition design.
• Focusing on pleiotropic beneficial effects (a single drug having multiple effects) to resolve disease.

The science is the strategy.

Patient-Centric Restoration

Statera Biopharma, Inc. is dedicated to patients by focusing on 'healthy today AND healthy tomorrow outcomes'. This isn't just a slogan; it drives their clinical choices. They prioritize the quality of life and future health, which they frame as a BENEFIT/risk calculation, a reversal of the typical 'RISK/benefit' rationalization common in drug development.

A concrete example is their lead investigational drug candidate, STAT-201. This program is focused on treating pediatric patients with Crohn's Disease, an inflammatory bowel disease. The U.S. Food and Drug Administration (FDA) granted STAT-201 Orphan Drug Designation for this indication. This designation is for drugs treating rare diseases, which often have a smaller market but a high unmet patient need, demonstrating a commitment to a vulnerable patient population over purely commercial targets. They completed a productive end of Phase 2 meeting with the FDA for the Phase 3 clinical trial in this area.

Strategic Focus & Portfolio Management

For a clinical-stage company with a negative Return on Equity (ROE) of -286.94%, capital allocation and strategic focus are defintely paramount. Their value of 'Strategic Focus' is demonstrated by their willingness to monetize or partner late-stage assets to streamline their pipeline and fund core AIMS programs.

In a major strategic move in February 2025, Statera Biopharma, Inc. sold the worldwide exclusive rights to its Phase III Toll-Like Receptor 5 (TLR5) Agonist, Entolimod, to Tivic Health. This asset, which targets acute radiation syndrome (ARS), was a late-stage product. This transaction allowed Statera Biopharma, Inc. to secure capital and sharpen its focus on its proprietary AIMS platform and its internal clinical programs like STAT-205 for acute and post-acute COVID infections. This is a clear signal of prioritizing platform development over maintaining every single asset. You can read more about the stakeholders in Exploring Statera Biopharma, Inc. (STAB) Investor Profile: Who's Buying and Why?.